Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HR+/HER2- Breast Cancer × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 50 Ovarian Neoplasms 8 Endometrial Neoplasms 6 Neoplasm Metastasis 5 Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Carcinoma, Non-Small-Cell Lung 3 Advanced Breast Cancer 3 Prostatic Neoplasms 2 Neoplasms by Site 2 Hereditary Sensory and Autonomic Neuropathies 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Breast Diseases 2 Advanced Solid Tumors 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Locoregional Recurrence 1 HR+/HER2- Breast Cancer 1 HR+ Breast Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1

Interventions

Letrozole 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡